Multiparametric Analysis of Cell-Free DNA in Melanoma Patients

Cell-free DNA in blood (cfDNA) represents a promising biomarker for cancer diagnosis. Total cfDNA concentration showed a scarce discriminatory power between patients and controls. A higher specificity in cancer diagnosis can be achieved by detecting tumor specific alterations in cfDNA, such as DNA integrity, genetic and epigenetic modifications. The aim of the present study was to identify a sequential multi-marker panel in cfDNA able to increase the predictive capability in the diagnosis of cutaneous melanoma in comparison with each single marker alone. To this purpose, we tested total cfDNA concentration, cfDNA integrity, BRAFV600E mutation and RASSF1A promoter methylation associated to cfDNA in a series of 76 melanoma patients and 63 healthy controls. The chosen biomarkers were assayed in cfDNA samples by qPCR. Comparison of biomarkers distribution in cases and controls was performed by a logistic regression model in both univariate and multivariate analysis. The predictive capability of each logistic model was investigated by means of the area under the ROC curve (AUC). To aid the reader to interpret the value of the AUC, values between 0.6 and 0.7, between 0.71 and 0.8 and greater than 0.8 were considered as indicating a weak predictive, satisfactory and good predictive capacity, respectively. The AUC value for each biomarker (univariate logistic model) was weak/satisfactory ranging between 0.64 (BRAFV600E) to 0.85 (total cfDNA). A good overall predictive capability for the final logistic model was found with an AUC of 0.95. The highest predictive capability was given by total cfDNA (AUC:0.86) followed by integrity index 180/67 (AUC:0.90) and methylated RASSF1A (AUC:0.89). An approach based on the simultaneous determination of three biomarkers (total cfDNA, integrity index 180/67 and methylated RASSF1A) could improve the diagnostic performance in melanoma.

[1]  H. Reber,et al.  Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. , 2006, Clinical chemistry.

[2]  Chunming Ding,et al.  Hypermethylated RASSF1A in maternal plasma: A universal fetal DNA marker that improves the reliability of noninvasive prenatal diagnosis. , 2006, Clinical chemistry.

[3]  A. Rudnicka,et al.  First-trimester or second-trimester screening, or both, for Down's syndrome. , 2005, New England Journal of Medicine.

[4]  D. Hodgson,et al.  Circulating tumour-derived predictive biomarkers in oncology. , 2010, Drug discovery today.

[5]  M. Fleischhacker,et al.  Circulating nucleic acids (CNAs) and cancer--a survey. , 2007, Biochimica et biophysica acta.

[6]  L. Kanter,et al.  NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  I. Cree,et al.  Circulating tumour markers can define patients with normal colons, benign polyps, and cancers , 2011, British Journal of Cancer.

[8]  D. Ichikawa,et al.  Quantification of circulating plasma DNA fragments as tumor markers in patients with esophageal cancer. , 2007, Anticancer research.

[9]  H. Donninger,et al.  The RASSF1A tumor suppressor , 2007, Journal of Cell Science.

[10]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[11]  D. Morton,et al.  CpG Island Methylator Phenotype Predicts Progression of Malignant Melanoma , 2009, Clinical Cancer Research.

[12]  Klaus Pantel,et al.  Cell-free nucleic acids as biomarkers in cancer patients , 2011, Nature Reviews Cancer.

[13]  R. Marais,et al.  331-338 News & Views MH.indd , 2009 .

[14]  K. Jung,et al.  Cell-free DNA in the blood as a solid tumor biomarker--a critical appraisal of the literature. , 2010, Clinica chimica acta; international journal of clinical chemistry.

[15]  G. Pfeifer,et al.  Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. , 2003, Cancer research.

[16]  David W. Hosmer,et al.  Applied Logistic Regression , 1991 .

[17]  D. Chan,et al.  Increased plasma DNA integrity in cancer patients. , 2003, Cancer research.

[18]  A. Giuliano,et al.  Prediction of breast tumor progression by integrity of free circulating DNA in serum. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  P. Meltzer,et al.  High frequency of BRAF mutations in nevi , 2003, Nature Genetics.

[20]  R. Elashoff,et al.  Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. , 2000, Cancer research.

[21]  J. Hanley,et al.  The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.

[22]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[23]  J. Ellinger,et al.  Cell-free circulating DNA: Diagnostic value in patients with renal cell cancer. , 2010, Anticancer research.

[24]  U. Lehmann,et al.  Detection of gene amplification in archival breast cancer specimens by laser-assisted microdissection and quantitative real-time polymerase chain reaction. , 2000, The American journal of pathology.

[25]  V. de Giorgi,et al.  Allele specific Taqman-based real-time PCR assay to quantify circulating BRAFV600E mutated DNA in plasma of melanoma patients. , 2010, Clinica chimica acta; international journal of clinical chemistry.

[26]  S. O’Day,et al.  Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  D. Canes,et al.  DNA Integrity Assay: A Plasma-Based Screening Tool for the Detection of Prostate Cancer , 2006, Clinical Cancer Research.

[28]  G. Mizejewski,et al.  Multi-marker testing for cancer: what can we learn from modern prenatal testing for Trisomy-21 , 2006, Cancer informatics.

[29]  M. Pierotti,et al.  Detection of mutated BRAFV600E variant in circulating DNA of stage III–IV melanoma patients , 2007, International journal of cancer.

[30]  P. Pinsky,et al.  Building Multi-Marker Algorithms for Disease Prediction—The Role of Correlations Among Markers , 2011, Biomarker insights.

[31]  R. Simon,et al.  Flexible regression models with cubic splines. , 1989, Statistics in medicine.

[32]  J. Califano,et al.  Increased plasma DNA integrity index in head and neck cancer patients , 2006, International journal of cancer.

[33]  D. Polsky,et al.  Detection of mutant BRAF alleles in the plasma of patients with metastatic melanoma. , 2007, The Journal of molecular diagnostics : JMD.

[34]  Douglas A. Wolfe,et al.  Nonparametric Statistical Methods , 1973 .

[35]  S. O’Day,et al.  Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. , 2006, Cancer research.

[36]  N. Dhomen,et al.  New insight into BRAF mutations in cancer. , 2007, Current opinion in genetics & development.

[37]  A. Paradiso,et al.  Biomarkers for Early Cancer Detection – Methodological Aspects , 2010, Breast Care.

[38]  G. Viale,et al.  Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas , 1996, International journal of cancer.

[39]  A. Mirmohammadsadegh,et al.  Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma. , 2006, The Journal of investigative dermatology.

[40]  V. de Giorgi,et al.  Circulating cell-free DNA in plasma of melanoma patients: qualitative and quantitative considerations. , 2011, Clinica chimica acta; international journal of clinical chemistry.